Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular Carcinoma-Reference-Cited by-同舟云学术

Multiple Immunomodulatory Strategies Based on Targeted Regulation of Proprotein Convertase Subtilisin/Kexin Type 9 and Immune Homeostasis against Hepatocellular Carcinoma

Published:2024-03-11 Issue:12 Volume:18 Page:8811-8826
ISSN:1936-0851
Container-title:ACS Nano
language:en
Short-container-title:ACS Nano

Author:

Fang Shiji¹²,Zheng Liyun¹²³,Shu Gao-Feng¹²⁴,Xiaoxiao Chen¹²,Guo Xiaoju¹²³,Ding Yiming¹,Yang Wenjing¹²,Chen Jiale¹²,Zhao Zhongwei¹²,Tu Jianfei¹²,Chen Minjiang¹²,Ji Jian-Song¹²³⁴^ORCID

Affiliation:

1. Zhejiang Key Laboratory of Imaging and Interventional Medicine, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui 323000, China

2. Clinical College of The Affiliated Central Hospital, School of Medcine, Lishui University, Lishui 323000, China

3. Department of radiology, Lishui Hospital of Zhejiang University, School of Medicine, Lishui 323000, China

4. Key Laboratory of Precision Medicine of Lishui, Lishui 323000, China

Funder

National Natural Science Foundation of China

the Key R&D Program of Lishui City

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acsnano.3c11775

Reference53 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Management of Hepatocellular Carcinoma

3. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

4. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

5. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial